ArticleGeneral psychiatry2025
Efficacy and safety of GW117 tablets in major depressive disorder: a randomised, double-blind, placebo-controlled, phase 2 dose-finding study.
Article in General psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06796868 (A Multicenter, Randomized , Double-blind, Parallel, Placebo-controlled Design Clinical Trial of GW117 Tablets), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized , Double-blind, Parallel, Placebo-controlled Design Clinical Trial of GW117 Tablets
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: GW117 (N-(2-(6-chloro-7-deuteromethoxy-naphthalen-1-yl) ethyl) acetamide) is a dual-acting agent (MT1/MT2 agonist, 5-HT Aims: To preliminarily evaluate the efficacy and safety of GW117 in major depressive disorder (MDD) and to explore the optimal dosing. Methods: A total of 280 eligible patients aged 18-65 years with MDD were randomly assigned (1:1:1:1) to 8 weeks of double-blind treatment with fixed doses of GW117 tablets (20, 40, 60 mg/day) or placebo. The primary endpoint was the change from baseline to Week 8 in the total score of the Hamilton Rating Scale for Depression-17 item (HAMD-17). Key secondary endpoints included changes in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score over the same period. Results: In the full analysis set (n=276), GW117 showed numerically greater reductions versus placebo in the HAMD-17 and MADRS total scores, as well as higher response rates at Week 8. However, these differences did not reach statistical significance, potentially due to a high placebo response and other contributing factors. In a post hoc analysis of an optimal subgroup (baseline HAMD-17 >24 or insomnia factor >4), GW117 showed efficacy in improving multidimensional symptoms, including insomnia. The 20 mg dose demonstrated a significant 3.66-point greater reduction in MADRS (p=0.026) and a 23.16% higher response rate (p=0.013) compared with placebo. GW117 was well-tolerated, with no cases of alanine aminotransferase or aspartate aminotransferase exceeding 3× the upper limit of normal and no concerning safety signals reported. Conclusions: This exploratory study found that GW117 demonstrated encouraging antidepressant efficacy and a favourable safety profile in patients with MDD. Although differences versus placebo did not reach statistical significance in the overall population, GW117 20 mg monotherapy showed significant improvements in multidimensional depressive symptoms, including insomnia, in the optimal response subgroup. No hepatotoxicity was reported, supporting its promising therapeutic potential for further clinical development. Trial registration number: NCT06796868. Date of retrospective registration: 23 April 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.